J Pediatr:儿童功能性便秘行物理治疗能否改善其症状?

2021-05-25 MedSci原创 MedSci原创

儿童功能性便秘是一个世界性的常见问题,面临着令人尴尬的症状,包括腹痛、排便疼痛、大便和大便失禁。近日,一项随机试验中,研究人员探究了物理治疗联合常规治疗与单纯的常规治疗相比对荷兰4-17岁的儿童功能性

儿童功能性便秘是一个世界性的常见问题,面临着令人尴尬的症状,包括腹痛、排便疼痛、大便和大便失禁。近日,一项随机试验中,研究人员探究了物理治疗联合常规治疗与单纯的常规治疗相比对荷兰4-17岁的儿童功能性便秘的治疗效果,研究结果已发表于J Pediatr

研究过程中,初级保健医生招募了被诊断为功能性便秘的儿童(n = 234),儿科医生招募了被诊断为功能性便秘的新转诊儿童(n = 11),随访8个月。常规治疗包括如厕训练、营养建议和泻药处方,而物理治疗则侧重于解决排便障碍问题。主要结果是8个月的治疗成功率,定义为没有功能性便秘而没有使用泻药。次要结果包括:无论是否继续使用泻药,都没有功能性便秘,以及整体感知的治疗效果。

 

对患儿进行随机分组,分别接受常规治疗联合物理治疗或常规治疗(每组67人),平均(SD)年龄为7.63.5)岁。意向治疗人群的纵向分析结果显示,在常规治疗的基础上增加物理治疗,治疗成功率并没有显著提高(校正后的相对风险[aRR] 0.8095%CI 0.44-1.30)。在4个月时,接受物理治疗的儿童的治疗成功率(17%)低于仅接受常规治疗的儿童(28%),但到8个月时,两组治疗成功率相似(分别为42%41%)。无论是否继续使用泻药,8个月内各组之间没有功能性便秘的儿童比例没有显著差异(aRR 1.1295% CI 0.82-1.34)。值得注意的是,家长报告物理治疗后患儿的整体症状改善明显多于常规治疗(aRR 1.4095% CI 1.00-1.73)。

综上所述,该研究并没有发现任何证据可以推荐在初级保健中对所有患有功能性便秘的儿童进行物理治疗。

 

原始出处:

 

Jojanneke J G T van Summeren, et al., Physiotherapy for Children with Functional Constipation: A Pragmatic Randomized Controlled Trial in Primary Care. J Pediatr. 2020 Jan;216:25-31.e2. doi: 10.1016/j.jpeds.2019.09.048.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639769, encodeId=8ad41639e69e6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 05 09:09:23 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971131, encodeId=dbb519e1131ba, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Sep 06 20:09:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728957, encodeId=9d6f1e289572b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jan 12 17:09:23 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915553, encodeId=c0b01915553eb, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Aug 01 20:09:23 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968479, encodeId=58339684e92f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61cb5465472, createdName=ms2000000690370536, createdTime=Tue May 25 22:13:29 CST 2021, time=2021-05-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639769, encodeId=8ad41639e69e6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 05 09:09:23 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971131, encodeId=dbb519e1131ba, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Sep 06 20:09:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728957, encodeId=9d6f1e289572b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jan 12 17:09:23 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915553, encodeId=c0b01915553eb, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Aug 01 20:09:23 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968479, encodeId=58339684e92f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61cb5465472, createdName=ms2000000690370536, createdTime=Tue May 25 22:13:29 CST 2021, time=2021-05-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639769, encodeId=8ad41639e69e6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 05 09:09:23 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971131, encodeId=dbb519e1131ba, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Sep 06 20:09:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728957, encodeId=9d6f1e289572b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jan 12 17:09:23 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915553, encodeId=c0b01915553eb, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Aug 01 20:09:23 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968479, encodeId=58339684e92f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61cb5465472, createdName=ms2000000690370536, createdTime=Tue May 25 22:13:29 CST 2021, time=2021-05-25, status=1, ipAttribution=)]
    2022-01-12 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639769, encodeId=8ad41639e69e6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 05 09:09:23 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971131, encodeId=dbb519e1131ba, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Sep 06 20:09:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728957, encodeId=9d6f1e289572b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jan 12 17:09:23 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915553, encodeId=c0b01915553eb, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Aug 01 20:09:23 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968479, encodeId=58339684e92f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61cb5465472, createdName=ms2000000690370536, createdTime=Tue May 25 22:13:29 CST 2021, time=2021-05-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1639769, encodeId=8ad41639e69e6, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 05 09:09:23 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971131, encodeId=dbb519e1131ba, content=<a href='/topic/show?id=5a1a3288305' target=_blank style='color:#2F92EE;'>#功能性便秘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32883, encryptionId=5a1a3288305, topicName=功能性便秘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Sep 06 20:09:23 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728957, encodeId=9d6f1e289572b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jan 12 17:09:23 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915553, encodeId=c0b01915553eb, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Aug 01 20:09:23 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968479, encodeId=58339684e92f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61cb5465472, createdName=ms2000000690370536, createdTime=Tue May 25 22:13:29 CST 2021, time=2021-05-25, status=1, ipAttribution=)]
    2021-05-25 ms2000000690370536

    学习了

    0

相关资讯

2018 APTA循证临床实践指南:先天性肌肉性斜颈症的物理治疗

先天性肌性斜颈是一种生后不就出现的明显的体位畸形,本文是对2013年指南的更新,主要针对先天性肌肉性斜颈症的预防教育,筛查,检查和评估,预后,首选干预措施,知情同意,直接干预中止,重新评估等内容提出指导建议。

NEJM:膝骨关节炎,采用物理治疗还是激素封闭治疗?

理疗和关节内注射糖皮质激素(俗称封闭治疗)都已被证明对膝关节骨性关节炎有临床疗效。但这两种治疗方法在缓解疼痛和改善生理功能方面的短期和长期疗效是否有差异尚不确定。

JAMA Neurol:帕金森氏症物理康复治疗有效性受到质疑

帕金森氏症的常见康复训练包括物理治疗与作业治疗等,旨在改善患者的生活质量。但在美国医学期刊上发表的一篇新研究认为,物理治疗与作业治疗的有效性值得怀疑。 英国伯明翰大学研究人员1月19日在《美国医学会杂志·神经病学卷》上发表研究说,对那些轻到中度帕金森氏症患者而言,物理治疗与作业治疗对他们中短期的日常活动没有产生积极影响,包括穿衣、刷牙等活动。 物理治疗与作业治疗均属于康复性训练,其中物理治疗主要改

BMC Musculoskelet Disord:术前物理治疗对退行性腰椎病患者行走能力和下肢力量的影响

腰椎退行性疾病是肌肉骨骼疾病中常见的疾病。当经过充分的康复治疗,影像学证实压迫性病变后,致残性疼痛和放射病变仍持续存在时,需要进行手术减压。手术前以增强功能能力为目的的预康复可以改善术前和术后的身体功

BMJ:上腹部手术后物理治疗可降低肺并发症风险

研究认为,对于上腹部手术患者,术后接受30分钟物理治疗可显著降低肺并发症风险

JAMA:非阻塞性半月板撕裂:物理治疗媲美手术?

关节镜下部分半月板切除术(APM)是骨科最常操作的手术之一。半月板撕裂在50岁以上人群中发生率高达60%且无膝关节疼痛。物理治疗(PT)对膝关节骨性关节炎的疼痛和功能改善有短期疗效,尽管近期多项研究显示APM治疗半月板撕裂不比PT更优效,且APM对此类关节疼痛和功能恢复的显着疗效仅能维持6个月,但依然未能降低治疗该病的手术操作。